

Quality Guru Nominated to Head CMS

BY ALICIA AULT

The White House announced on April 19 that it has nominated Dr. Donald Berwick to lead the Centers for Medicare and Medicaid Services.

The nomination of Dr. Berwick, a pediatrician who is president and chief executive officer of the Institute for Healthcare Improvement, had been rumored for weeks.

In a statement released by the White House, President Obama said, "Dr. Berwick has dedicated his career to improving outcomes for patients and providing better care at lower cost. That's one of the core missions facing our next CMS Administrator."

Physicians' organizations began to express enthusiasm for Dr. Berwick's nomination even before it was made official. The American Medical Association praised Dr. Berwick's "visionary leadership efforts" in quality and patient safety in a statement by Dr. Nancy H. Nielsen, the AMA's immediate past president.

With the passage of health reform and the continuing lack of a permanent solution for the fee cuts threatened by Medicare's sustainable growth rate (SGR) formula, Dr. Berwick will have a full plate if he is confirmed by the Senate.

Physicians, hospitals, insurers, consumers, and pharmaceutical and medical device manufacturers all are hoping to influence how the law is implemented.

The medical device industry lobby, AdvaMed, issued a statement praising Dr. Berwick's "compelling vision," but reminded him also of what he will be taking on. "There is perhaps no more important job in health care," said Stephen J. Ubl, president and CEO of AdvaMed. "The decisions made by Dr. Berwick will affect the lives of America's seniors and every health care provider, and CMS will play a pivotal role in implementing the comprehensive health reform program recently enacted by Congress."

For his part, Dr. Berwick said in a statement that he felt "flattered and humbled" at his nomination. He added, "If confirmed by the U.S. Senate, I would welcome the opportunity to lead CMS because it offers the chance to help extend the effort to improve America's health care system—the very vision that led to the founding of the Institute for Healthcare Improvement."

Dr. Berwick is affiliated with Children's Hospital Boston, and is a consultant in pediatrics at Massachusetts General Hospital. He is an elected member of the Institute of Medicine, and previously chaired the National Advisory Council for the federal Agency for Healthcare Research and Quality. He also served on President Clinton's Advisory Commission on Consumer Protection and Quality in the Healthcare Industry in 1997 and 1998. ■

Experts Analyze Ways to Make HIT Safer

BY MARY ELLEN SCHNEIDER

As physicians and hospitals begin to implement electronic health record systems in the hopes of earning financial incentives from the federal government, experts are considering how to ensure patient safety when working with health information technology.


The Health IT Policy Committee, which makes recommendations to the federal National Coordinator for Health

Information Technology, met this spring to discuss some of the areas where potential patient safety hazards exist. Topping the list were technology issues, such as software bugs, interoperability problems, and implementation and training deficiencies. Another major area of concern is the interaction of people and technology.

According to Paul Egerman, who chairs the Certification/Adoption Workgroup of the Health IT Policy

Committee, straightforward problems with technology are actually the minority when it comes to safety issues. While these problems can be difficult to uncover, once they are discovered they can usually be easily and rapidly fixed.

The majority of safety issues surrounding health IT involve multiple factors. That complicates things, Mr. Egerman said, because that means that even if the technology worked perfectly, there could still be problems. "There



Indication

FLECTOR® Patch (diclofenac epolamine topical patch) 1.3% is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions.

Carefully consider the potential benefits and risks of FLECTOR® Patch and other treatment options before deciding to use FLECTOR® Patch. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals.

Important Safety Information

Cardiovascular (CV) risk

- NSAIDs may cause an increased risk of serious CV thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with CV disease or risk factors for CV disease may be at greater risk
- FLECTOR® Patch is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft surgery

Gastrointestinal (GI) risk

- NSAIDs cause an increased risk of serious GI adverse events at any time during use and without warning symptoms including bleeding, ulceration,

and perforation of the stomach or intestines, which can be fatal. Elderly patients are at greater risk of serious GI events

FLECTOR® Patch is contraindicated in patients with known hypersensitivity to diclofenac. FLECTOR® Patch should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients.

FLECTOR® Patch should not be applied to nonintact or damaged skin resulting from any etiology, eg, exudative dermatitis, eczema, infected lesion, burns, or wounds.

NSAIDs, including FLECTOR® Patch, can lead to new onset or worsening of hypertension, contributing to increased incidence of CV events. Fluid retention and edema have been observed in some patients taking NSAIDs. Use with caution in patients with hypertension, fluid retention, or heart failure.

Elevations of one or more liver tests may occur during therapy with FLECTOR® Patch. If abnormal liver tests persist or worsen, if clinical signs and/or symptoms